The Johnson & Johnson Family of Diabetes Companies is proud to be a Principal Corporate Collaborator for the Together 2 Goal® campaign, and to provide participating medical groups, health systems, healthcare providers, and patients with tools and resources through its CarePath Healthy Engagements program to help improve the care for people with type 2 diabetes (T2D). To learn more about this program and the available resources, click here.

Help impact adherence with the power of mobile technology
The Care4today® Mobile Health Manager harnesses the power of mobile technology to help patients manage their medication schedules and more, across smart and feature phone platforms. The app is available in multiple languages in the US and abroad. Over 375,000 downloads, thousands of users* sending over 190,000 reminders/day. Click here to learn more.

Identify areas of excellence and opportunity within your diabetic patient population
QualityPATH (Population Analyzer Tool for Health systems) segments and prioritizes your patient populations to support the improvement of healthcare outcomes in T2D. The software evaluates your EHR and claims data to identify gaps in T2D care. It generates actionable reports to guide and monitor improvements in your quality metrics. Click here to learn more.

Leverage a hub of resources specifically for health care professionals

As a longtime mental health and well-being leader, advocate and innovator, Johnson & Johnson is bringing its resources and expertise to support the mental health and well-being of healthcare professionals. There are a variety of learning opportunities and programs available on the Johnson & Johnson Institute website for health workers to build their resilience, mental strength and overall wellness. Click here to learn more.

Learn about blood clot risk for patients with Type 2 diabetes

The CLOT WISE™ program includes videos to help you and your patients learn more about the underlying risk for blood clots related to coronary artery disease (CAD) and peripheral artery disease (PAD), why aspirin alone may not be enough, and how to further reduce your patients’ risk for cardiovascular events. Click here to learn more.